Erlotinib, Gemcitabine, and Radiation Therapy in Treating Patients With Locally Advanced Unresectable Pancreatic Cancer

NCT00063947 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

28

Enrollment

NIH

Sponsor class

Conditions

Adenocarcinoma of the Pancreas
Recurrent Pancreatic Cancer
Stage II Pancreatic Cancer
Stage III Pancreatic Cancer

Interventions

DRUG: erlotinib hydrochloride
DRUG: gemcitabine hydrochloride
RADIATION: radiation therapy
OTHER: laboratory biomarker analysis

Sponsor

National Cancer Institute (NCI)